However, Dahman et al. recommended the use of glutamic pyruvic transaminase (SGPT) and gamma-glutamyl transferase (γ-GT) serum levels as a potential prognostic marker for non-alcoholic fatty liver disease in Type 2 diabetes mellitus patients with dyslipidemia [19], precisely because there was a liver dysfunction in their study group. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.